Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.
1. A compound of Formula I-2 or a pharmaceutically acceptable salt, solvate or prodrug thereof:
2. A compound of Formula I-2, or a pharmaceutically acceptable salt or solvate thereof:
3. A composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt, solvate or prodrug thereof.
4. A composition comprising the compound of claim 2 , or a pharmaceutically acceptable salt or solvate thereof.
5. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt or solvate.
6. The composition of claim 5 , wherein the composition further comprises a pharmaceutically acceptable carrier.
7. The composition of claim 6 , wherein the composition is suitable for oral administration.
8. The composition of claim 6 , wherein the composition is suitable for intravenous (IV) administration.
9. The composition of claim 7 , wherein the composition is a tablet, buccal tablet, troch, capsule, caplet, pellet, granule, lozenge, chewing gum, powder, syrup, elixir, wafer, aqueous solution or suspension.
10. The composition of claim 5 , wherein the composition comprises 0.1 mg to 1000 mg of the compound of Formula I-2, or a pharmaceutically acceptable salt or solvate thereof.
11. The composition of claim 5 , wherein the composition comprises 500 mg of the compound of Formula I-2, or a pharmaceutically acceptable salt or solvate thereof.
12. The composition of claim 5 , wherein the composition comprises 10 mg to 250 mg of the compound of Formula I-2, or a pharmaceutically acceptable salt or solvate thereof.
13. The composition of claim 5 , wherein the composition comprises 0.5 mg to 250 mg of the compound of Formula I-2, or a pharmaceutically acceptable salt or solvate thereof.
14. The composition of claim 5 , wherein the composition comprises 0.5 mg to 50 mg of the compound of Formula I-2, or a pharmaceutically acceptable salt or solvate thereof.
15. The composition of claim 5 , wherein the composition comprises 10 mg to 50 mg of the compound of Formula I-2, or a pharmaceutically acceptable salt or solvate thereof.
16. The composition of claim 5 , comprising the compound of Formula I-2, or a pharmaceutically acceptable salt thereof.
17. A method for activating a serotonin receptor in a subject comprising administering the compound of claim 1 , or a pharmaceutically acceptable salt, solvate or prodrug thereof, to the subject.
18. A method of treating a subject having a condition that is treated by activation of a serotonin receptor, comprising administering the compound of claim 1 , or a pharmaceutically acceptable salt solvate or prodrug thereof.
19. The method of claim 18 , wherein the condition is a neurological or psychiatric disorder.
20. The method of claim 18 , wherein the condition is psychosis or psychotic symptoms.
21. The method of claim 18 , wherein the condition is a mental illness disorder.
22. The method of claim 21 , wherein the mental illness disorder is selected from generalized anxiety disorders, phobias, depression, mood disorders, psychotic disorders, eating disorders, impulse control disorders, addiction disorders, personality disorders, dissociative disorders, factitious disorders, sexual disorders, gender disorders, somatic symptom disorders, attentional disorders, tic disorders, sleep-related disorders, and a combination thereof.
23. The method of claim 21 , wherein the mental illness disorder is selected from panic disorder, social anxiety disorder, hopelessness, loss of pleasure, fatigue, suicidal thoughts, bipolar disorder, cancer-related depression, anxiety, cyclothymic disorder, hallucinations, delusions, schizophrenia, anorexia nervosa, bulimia nervosa, binge eating disorder, pyromania, kleptomania, compulsive gambling, alcohol addiction; drug addiction, antisocial personality disorder, obsessive-compulsive personality disorder, paranoid personality disorder; obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), stress response syndromes, sexual dysfunction, gender identity disorder, paraphilia, attentional deficit disorder, attentional deficit hyperactivity disorder, Tourette's syndrome, and a combination thereof.
24. The method of claim 21 , wherein the mental illness disorder is selected from hallucinations, delusions, and a combination thereof.
25. The method of claim 24 , wherein the hallucinations are selected from visual hallucinations, auditory hallucinations, olfactory hallucinations, gustatory hallucinations, tactile hallucinations, proprioceptive hallucinations, equilibrioceptive hallucinations, nociceptive hallucinations, thermoceptive hallucinations, chronoceptive hallucinations and a combination thereof.
26. The method of claim 21 , wherein the mental illness disorder comprises cognitive impairment, ischemia, neurodegeneration, refractory substance use disorders, sleep disorders, pain, obesity, eating disorders, seizure disorders, neuronal cell death, excitotoxic call death, or a combination thereof.
27. The method of claim 18 , wherein the condition is a CNS disorder that is a form of dementia.
28. The method of claim 18 , comprising administering the compound of Formula I-2, or a pharmaceutically acceptable salt or solvate thereof.
29. The method of claim 18 , wherein the subject is a feline or canine and the condition is anxiety, fear, stress, sleep disturbances, cognitive dysfunction, aggression, or a combination thereof.